The United States government is currently piloting an ambitious program leveraging artificial intelligence to inform insurance-coverage decisions, a move that could profoundly reshape the contentious landscape of prior authorization in healthcare. This initiative, spearheaded by the Trump administration, aims to streamline processes and reduce what it identifies as unnecessary medical spending. However, the introduction of AI into this critical facet of healthcare administration is met with both cautious optimism for its potential to expedite claims and significant apprehension regarding its capacity to exacerbate wrongful denials and compromise patient access to medically necessary care.
Understanding Prior Authorization: A System Under Scrutiny
For countless Americans, the journey to receiving physician-recommended medical care is often fraught with bureaucratic hurdles, primarily in the form of prior authorization. This process, requiring pre-approval from health insurers for specific prescription medications, medical procedures, or services, has become a notorious source of frustration and anxiety. Personal stories abound, detailing the tribulations patients endure as they navigate complex requirements, often leading to significant delays or outright denials for essential treatments.
The original intent behind prior authorization was judicious: to serve as a vital check on overuse, control healthcare spending, and ensure that patients receive services or technologies for which there are no less costly, equally effective alternatives. In an ideal scenario, it acts as a gatekeeper against wasteful spending and medically inappropriate care. However, in practice, the system has become synonymous with administrative burden and significant impediments to timely care. A substantial majority of physicians consistently voice concerns about these care delays, which can tragically lead patients to abandon recommended treatments while awaiting their insurance company’s verification of eligibility and medical necessity. When care is denied, patients are left with the option to submit an appeal, a process that invariably demands more time, resources, and emotional fortitude.
The Promise and Peril of Artificial Intelligence in Healthcare
The advent of artificial intelligence offers a tantalizing prospect for revolutionizing various sectors, and healthcare administration is no exception. With its unparalleled ability to efficiently process and sort through vast reams of information, AI could theoretically expedite the approval of unambiguously allowable claims. This efficiency gain holds the promise of significantly reducing care delays, thereby improving patient outcomes and alleviating the administrative strain on healthcare providers. Proponents envision a future where routine approvals are instantaneous, freeing up human reviewers to focus on more complex cases requiring nuanced clinical judgment.
However, the integration of AI into prior authorization is far from universally welcomed. It is currently facing considerable resistance, driven by fears that AI-driven prior authorization models may, paradoxically, increase wrongful denials of health insurance coverage. A recent 2025 American Medical Association (AMA) survey of physicians underscored these anxieties, revealing significant concern about the application of AI tools. A striking 61 percent of doctors expressed worry that AI would exacerbate denials of what they deem are necessary treatments, raising serious questions about the ethical implications and potential for algorithmic bias in healthcare decisions.
Advocacy groups, including the AMA, are actively pushing for safeguards. The AMA advocates for requiring insurers to provide detailed clinical reasoning to justify any denials of coverage. Furthermore, they emphasize the critical need for more transparency regarding the underlying AI algorithms, asserting that clinicians and patients deserve to understand the basis of these automated decisions. Health policy analyst Camm Epstein succinctly captured this sentiment in an email to Undark, stating that “AI should be used to make appropriate care easier to approve, not necessary care easier to deny.” This statement encapsulates the core tension at play: whether AI will be a tool for enablement or an instrument for restriction.
The WISeR Model: Trump Administration’s AI-Driven Initiative
In an effort to harness AI for cost reduction, the Trump administration has launched a pilot program in six states. This year, the Centers for Medicare and Medicaid Services (CMS) initiated a demonstration project known as WISeR, or the Wasteful and Inappropriate Service Reduction Model. Designed to leverage AI in reducing waste and fraud within original Medicare, WISeR specifically aims to decrease unnecessary procedures. The project is slated to run through December 2031 and combines advanced technologies such as machine learning with human clinical review. Its focus is on evaluating services CMS believes may be particularly vulnerable to overuse, fraud, and abuse, including procedures like skin and tissue substitutes, electrical nerve stimulator implants, and knee arthroscopy for knee osteoarthritis.
This initiative marks a significant shift, as prior authorization has been extensively utilized in Medicare Advantage—the privately run alternative to original Medicare—but has rarely been deployed in original Medicare itself. This expansion into original Medicare, a system traditionally less encumbered by pre-approval mandates, raises immediate concerns among patient advocates and providers. The apprehension stems from the documented issues within Medicare Advantage, where insurers issue millions of full or partial claim denials annually based on prior authorization. Federal government reports, including those issued in June, have highlighted instances where plans sometimes reject requests for essential services like skilled nursing and rehabilitation admissions, even when medically appropriate.
A particularly contentious aspect of the WISeR model is its financial incentive structure. Vendors participating in the WISeR model, who are hired to carry out the AI-driven prior authorization reviews, earn a share of what CMS refers to as “averted expenditures.” This means these vendors directly profit from rejecting care requests, creating a potential conflict of interest. Critics argue that this model could incentivize denials rather than ensuring appropriate care, pointing to long-standing concerns regarding profit-making on the basis of discouraging patients from getting medically necessary care. Several lawmakers have responded by introducing resolutions and amendments to block funding for the WISeR model, citing grave threats to patient access.
Patient and Provider Experiences: A Landscape of Delays and Denials
The impact of prior authorization, whether human or AI-driven, reverberates deeply through the lives of patients and the practices of healthcare providers. The public overwhelmingly views prior authorization as a major burden, as evidenced by a KFF Health Tracking Poll. In Medicare Advantage, which now enrolls roughly 55 percent of Medicare-eligible seniors and disabled individuals, the scale of denials is staggering. Insurers made nearly 53 million prior authorization determinations in 2024, with a significant number resulting in full or partial claim denials. While Medicare Advantage plans overturned a high percentage of denials upon appeal (81% in 2024), this fact itself raises questions: if so many denials are reversed, were they initially justified? The appeals process, though a lifeline, is often complicated and cumbersome, pushing patients to the brink. NBC News reported that some patients become "stuck in prior authorization purgatory," running out of time or viable treatment options while awaiting resolution.
A newly released Commonwealth Fund survey in June 2026 further illuminated the widespread impact. Approximately one in five American working-age adults with private insurance reported that either they or a family member were denied insurance coverage for physician-recommended medical care in 2025. The consequences were significant: 41 percent of those who experienced a prior authorization denial said it delayed their care, and more than a quarter reported that their health problem worsened as a direct result. These statistics underscore the tangible and often severe repercussions of a system designed for cost control but often perceived as an impediment to health.
A Chronology of Reforms and Responses: Navigating the Regulatory Maze
Recognizing the pervasive issues, both government bodies and private insurers have attempted to implement improvements. A significant step was taken by the former President Joe Biden’s administration, which issued a rule in 2024 designed to reduce delays for patients with government-run plans and streamline the prior authorization process for physicians. This rule mandated that insurers make certain prior authorization decisions within 72 hours for urgent requests and seven calendar days for non-urgent requests. These timeline requirements officially went into effect on January 1 of this year for most health plans in the public sector, aiming to inject much-needed predictability and speed into the process.
Concurrently, last year, the Trump administration, alongside major insurers, pledged to further streamline and accelerate prior authorization processes across the board. Private insurance companies, in response to growing pressure, vowed to standardize electronic requests by 2027 and committed to "reduce the volume of medical services subject to prior authorization" by 2026. This commitment included common, high-volume procedures such as colonoscopies and cataract surgeries, signaling an acknowledgement of the system’s current inefficiencies and patient burden.
In a recent development, industry groups released data suggesting a positive trend. An industry-based survey revealed that between June 2025 and April 2026, requests for prior authorization declined by 11 percent. While this indicates a reduction in the sheer volume of requests, it remains unknown whether the underlying denial rate has also decreased, a critical metric for assessing the true impact on patient access. Furthermore, in response to an industry group survey conducted last year, all responding health plans agreed with the statement: "AI or algorithms without clinician or practitioner review are not used to deny prior authorization requests that involve medical necessity or clinical considerations." Insurers also promised more transparency around the clinical reasoning underlying prior authorization decisions, a direct response to calls from advocacy groups like the AMA.
The Contradiction and Criticism: A Divided Approach
Despite these pledges and regulatory actions, a curious contradiction emerges in the Trump administration’s approach to prior authorization. While CMS is actively expanding its use in original Medicare through the AI-driven WISeR model, the agency simultaneously advocates for lessening and streamlining its use by private insurers, including Medicare Advantage plans. This dual strategy was highlighted by CMS Administrator Mehmet Oz, who issued a stern warning to insurance company executives: "If you don’t do it yourselves, then we’re going to do it for you," he declared on the National News Desk, threatening federal regulation if the industry failed to ease the burden of prior authorization.
This seemingly contradictory stance fuels criticism from various quarters. Wendell Potter, a prominent advocate for health insurance reform and a former executive at health insurer Cigna, has publicly covered the political pushback against the WISeR model. Zena Wolf, a researcher with the Center for Health & Democracy, further cited investigations by major news outlets like the Washington Post, KFF Health News, and the Seattle Times. These reports suggest that in its initial months, the WISeR model has indeed caused delays in care and denials in some instances across the six pilot states. Moreover, despite the promise of automation, critics argue that the system often imposes a high administrative burden on healthcare providers, who must still contend with the additional work involved in appealing and managing denials.
The underlying fear, articulated by Jared Dashevsky, a physician and founder of Healthcare Huddle, is that AI, rather than fixing a broken system, is merely automating its flaws. He wrote that while AI could "eliminate barriers, reduce administrative waste, give us more time with patients," that’s "not what’s being built." Instead, he warns of an "arms race to deny faster and appeal faster," leading to "more automation of a broken system that shouldn’t exist in its current form." This perspective encapsulates the deep skepticism that pervades the healthcare community regarding AI’s potential to genuinely improve patient care within the current profit-driven insurance framework.
The Ethical Quandary: Profit Motives and Patient Care
The WISeR model’s incentive structure, where vendors profit from "averted expenditures," represents a significant ethical quandary. This direct financial gain for denying care requests points to a broader, long-standing concern within the American healthcare system: the potential for profit motives to overshadow the fundamental goal of ensuring medically necessary care. This issue is not new; federal reports have previously documented how Medicare Advantage organizations sometimes deny requests for services that meet coverage rules, only to overturn a significant portion of these denials upon appeal. This pattern suggests that initial denials may sometimes be driven by financial considerations rather than purely clinical ones.
The introduction of AI into this equation amplifies these concerns. If algorithms are designed or incentivized to err on the side of denial, or if their parameters are set to maximize "savings," the risk of disproportionately impacting vulnerable patient populations or denying care that is genuinely necessary increases. This potential for profit-driven algorithms to act as gatekeepers to care has prompted lawmakers to introduce measures to block WISeR funding, reflecting a legislative anxiety about unintended consequences and the erosion of patient trust.
The Path Forward: Balancing Innovation, Access, and Oversight
The integration of AI into prior authorization protocols presents a complex challenge that demands careful navigation. While the potential for increased efficiency and reduced administrative waste is undeniable, the overriding priority must remain patient access to timely and appropriate medical care. Achieving this balance requires robust oversight, unwavering transparency, and stringent ethical guidelines for AI development and deployment in healthcare.
Crucially, the debate highlights the ongoing necessity of human review in critical medical decisions. While health plans have pledged that AI will not be used to deny requests without clinician review, the effectiveness of this safeguard hinges on the quality and independence of such reviews. Furthermore, the appeals process, though often burdensome, serves as a vital safety net, and its efficiency and fairness must be continuously improved.
Ultimately, the future of prior authorization in an AI-driven era will depend on whether policymakers, insurers, and technology developers can collaborate to build systems that truly serve patients and providers, rather than merely automating existing inefficiencies or exacerbating inherent conflicts of interest. The fundamental tension between cost control and patient well-being, now augmented by the power of artificial intelligence, will continue to shape the trajectory of healthcare administration for years to come.
Conclusion: An Unfolding Experiment
The government’s pilot program employing AI for insurance-coverage decisions is an unfolding experiment with profound implications. While the promise of theoretically expedited claims and reduced administrative burden is appealing, the concerns surrounding increased denials, lack of transparency, and potential profit-driven motives are significant. The diverse reactions from physicians, patient advocates, and lawmakers underscore the contentious nature of this technological integration. As the WISeR model progresses and private insurers continue to adapt their prior authorization practices, the critical question remains: will AI ultimately serve as a catalyst for a more efficient and patient-centered healthcare system, or will it merely amplify the existing flaws of a system already struggling under the weight of bureaucracy and competing interests? The answer will define a new era for healthcare access in America.
